11/13/2025
Program Now Available: 10th DIA Cell and Gene Therapy Products Symposium in Japan
[Session Highlight]
Stable Manufacturing of Cellular Therapeutic Products: Towards Consistent Manufacturing Processes Throughout the Product Lifecycle
This session aims to ensure consistent manufacturing across the product lifecycle by explaining and discussing current support measures. The Ministry of Economy, Trade and Industry will first introduce initiatives in regenerative medicine, including promoting the use of CDMOs (Contract Development and Manufacturing Organizations) for pharmaceutical development. Pharmaceutical companies will then share scenarios and challenges in applying core technologies. The ISO/TC 276 Mirror Committee will present an overview and practical use of standards—particularly JIS Q 2101: Cell Manufacturing Process Management System, published in February 2025. Finally, a panel discussion with experts from PMDA and leading CDMOs will explore the adequacy of these support measures.
SESSION CHAIR:
◾ Maki Tanaka Maki Tanaka (Takara Bio Inc.)
◾ Ikuo Kawauchi (FUFIFILM Holdings Corporation)
SPEAKERS:
◾ Shoki Nishio (Ministry of Economy, Trade and Industry(METI))
◾ Mika Yoshimatsu (T Cell Nouveau Inc.)
◾ Ryutaro Hirasawa, PhD (Daiichi Sankyo Co., Ltd.)
◾ Ikuo Kawauchi (FUFIFILM Holdings Corporation)
◾ Ryuji Kato (Tokai National Higher Education and Research System, Nagoya University)
PANELISTS:
◾ Kenichiro Maeda (Pharmaceuticals and Medical Devices Agency (PMDA))
◾ Junichi Mineno (Takara Bio Inc.)
Take advantage of our early bird team rate – register today and save: https://ow.ly/OFK250XqRGX.